Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.
FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer
Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC